Center City, Philadelphia, PA
There is an immediate opening for post-doctoral fellow interested in cancer initiation in a funded, high-level cancer research laboratory. The Eischen laboratory https://www.eischenlab.com/ needs highly motivated postdoctoral fellow who will be defending their PhD soon or are not more than 2 years out of their PhD. The Postdoctoral fellow should be interested in genetic, molecular, or biochemical mechanisms of tumor development.
The laboratory utilizes genetically engineered mouse models, primary cell culture, retroviral gene transfer technologies, protein purification, genomics, bioinformatics, and patient sample analysis, to answer biological questions related to tumor initiation. We have publish in high profile journals (e.g., Edmonds et al. J. Clinical Inves 2016, Mitra et al. Nature Comm 2017, Adams et al. J. Clinical Inves 2017, Adams et al Clinical Can Res, Pucetti et al Cancer Res 2019.
Project 1 is an investigation of the Myc oncogenic transcription factor and a novel regulator we discovered. A new mouse model and, epigenetic, biochemical, cellular, genomic, and bioinformatic approaches are being used to elucidate its mechanism of action and its contribution to Myc activity and human lymphoma and other malignancies.
Project 2 is focused on lung adenocarcinoma and the miRNA that contribute to its development, growth, and progression. Mouse models and various approaches to evaluate miRNA and their targets are utilized.
Project 3 focuses on Mdm2 and Mdmx and their p53-independent function in DNA break repair. This project involves biochemical, cellular, and mouse modeling approaches to characterize Mdm2 and Mdmx function in inhibiting DNA break repair and how this function can be capitalized on for the treatment of malignancies. New small molecule inhibitors are also being tested.
Interested individuals must be skilled in cancer biology techniques (e.g., cell culture, mouse modeling, biochemistry, flow cytometry, etc.) Ph.D., in structural biology and molecular biology required.
Jefferson Health delivers state of the art healthcare services to patients throughout the Delaware Valley and southern New Jersey. Jefferson (Philadelphia University + Thomas Jefferson University) provides more than 8,400 full and part-time students from nearly 40 states and 40 countries with 21st century professional education. Combined, we have over 30,000 employees.
Jefferson Health, with 14 hospitals (seven are Magnet designated by the ANCC for nursing excellence) and 40+ outpatient and urgent care locations, offers a broad range of primary and complex, highly specialized care that touches the lives of more than four million patients annually. U.S. News & World Report has ranked Thomas Jefferson University Hospital among the nation’s best in eight specialties. Jefferson Health also includes the NCI designated Sidney Kimmel Cancer Center; it is one of only 70 such centers in the nation.
Thomas Jefferson University has ten colleges and three schools that offer more than 160 undergraduate and graduate programs. Our University is dedicated to inter-professional and transdisciplinary approaches to learning that offer a vibrant and expandable platform for professional education. Through this unique model, we are preparing our students for current and yet to be imagined careers.
As an employer, Jefferson maintains a commitment to provide equal access to employment. Jefferson values diversity and encourages applications from women, members of minority groups, LGBTQ individuals, disabled individuals, and veterans.